Articles related to PRODUCT RECALL

Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

The FDA gave the recall a class 2 risk level, meaning that drinking the creamers ‘may cause temporary or medically reversible adverse health consequences,’ or that the possibility of serious health consequences is ‘remote.’

Healthcare providers should be vigilant for patients presenting with neurological symptoms, especially if there’s a history of consuming canned tuna products.

N-nitroso-duloxetine poses increased cancer risk at higher concentrations and extended exposure periods, prompting FDA-mandated strict limits on nitrosamine levels in medications.

Recent research indicates that pharmaceutical nitrosamine contamination presents broader implications for drug safety, with increasing evidence of genotoxic and mutagenic effects even at trace levels.

Manufacturing violations at an Indian facility have triggered a recall of 15 million OTC pain patches, raising concerns about product quality and patient safety across multiple widely-used brands.